An interventional study of Lithium Orotate (LiO) and Placebo in Cognitive Impairment, Dementia and Alzheimer Disease, sponsored by Massachusetts General Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital — 14 open to participants now, 16 under way, none of them phase 3. Cognitive Dysfunction · Massachusetts General Hospital.
Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, this one is the 3rd largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2026, is one of 17 with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 33rd registered.
3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
Browse Cognitive Dysfunction studies →14 of the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 55+
Massachusetts General Hospital · Sites in United States
Ages 40–99 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 50–80 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 25–50
Massachusetts General Hospital · Sites in United States
Ages 50+
By country, each count listing its studies:
Of the 753 Cognitive Dysfunction studies recruiting now, 364 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 4 2
First in 2005; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 64 across 2,797 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 40 across the 27 interventional studies, 226 across the 6 observational. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,590 studies on the registry; 447 are open to participants now.
Of its 223 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
10 of the studies in Cognitive Dysfunction by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05857137Massachusetts General HospitalPsychosis TMS Study | 2026-11-30 |
| NCT05881239Massachusetts General HospitalDigital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD | 2026-12-30 |
| NCT06538311Massachusetts General HospitalTranscranial Magnetic Stimulation Treatment for Alzheimer's Disease | 2027-03-31 |
| NCT07236190Massachusetts General HospitalBiomarker-based Trial of NPC-1 for Alzheimer's Pathology | 2027-06 |
| NCT05904132Massachusetts General HospitalIndividual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease | 2027-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
LiDS is a dosing study to evaluate the safety, tolerability, and feasibility of daily oral Lithium Orotate (LiO) in aging adults at increased risk for progression of cognitive problems, including Alzheimer's disease and related dementias.
Lithium orotate (LiO), a compound combining lithium with orotic acid, has shown remarkable neuroprotective effects in preclinical studies by our group - reducing amyloid plaques, lowering brain inflammation, and improving memory. Early human studies suggest that low doses may be safe and potentially beneficial for brain function. Given its affordability, accessibility, and considerably lower side effect profile compared to other lithium-based compounds, LiO warrants further human investigation. However, more information must first be obtained regarding the effects of LiO on the human body, focused on the safety and tolerability of LiO supplementation at various amounts. We propose a 12-week dose-ranging study to evaluate the safety, tolerability, and feasibility of daily oral LiO at different doses of elemental lithium among aging adults across a cognitive spectrum and at risk for progressing to worsening cognitive function, including those with subjective cognitive complaints, mild objective cognitive impairment, or moderate objective cognitive impairment. This represents the most relevant study population in whom to evaluate potential effects of LiO on the human body.
Specific Aims and Objectives
The primary objectives for this dose-ranging trial are to assess:
Safety: Side effects will be tracked via serial REDCap web-based surveys. Blood samples will be collected at baseline and prior to the final study visit (between 8 and 12 weeks during randomized treatment) with thyroid, liver, and kidney function monitoring.
Tolerability: Participants' adherence to assigned study pills and study withdrawal rates will be monitored through regular web-based surveys.
Feasibility: Feasibility will be determined by the successful completion of study procedures, including recruitment and enrollment rates; compliance rates with web-based surveys; participation rates in blood sample collections; change in lithium levels in active vs. placebo groups.
Secondary objectives will involve use of: 1) survey measures of mood, thinking, or functioning, as these represent important additional safety variables (i.e., change in mood or suicidal ideation) and/or common nuisance side effects (i.e., changes in subjective cognition and everyday functioning) that may account for a large share of differences in tolerability of lithium; 2) additional blood biomarkers designed to further capture the effects of the supplement on the human body.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 60 years or older at study entry Self-reported ability to read and understand English. As all study surveys have been validated in English, we will limit participation to potential subjects able to read English.
Able to provide
Must meet criteria for one of the three following cognitive statuses:
Cognitively normal/unimpaired, (TICS-41 score ≥34 with presence of subjective cognitive concerns and without significant hearing impairment
For those without hearing impairment, TICS-41 score 23 to \<34 (mild objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of MCI
For those without hearing impairment, TICS-41 score >15 to \<23 (moderate objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of mild-stage AD dementia
Must be able and willing to adhere to study procedures
Participants with moderate objective impairment or clinician diagnosis of AD dementia must have a study partner willing to participate in the study with them.
Exclusion Criteria:
Lithium-specific exclusions
History of lithium toxicity, intolerance or
Use of any lithium formulation in the last six months
History of diagnosed kidney disorders (e.g., chronic kidney disease, dialysis or renal transplant, acute kidney injury within past 6 months)
Unstable thyroid disorders (e.g., medication change in the last 90 days) or history of thyroid surgery, radioactive iodine treatment or active thyroiditis in the last 90 days
Unwilling to forego use of any non-study lithium formulation during the trial
Self-reported major psychiatric and neurological disorders
Bipolar disorder, schizophrenia, or unstable major depression (e.g., recent hospitalization, medication change in the last 90 days).
To optimize participant safety and to ensure that individuals with any degree of suicidal ideation at baseline are not included in the study, the presence of any suicidal ideation at screening will be defined as a score of >0 on PHQ-9 Item 9 or as spontaneously reported during screening. The PHQ-9 will also be administered at 6- and 12-week follow-up time points as a safety monitoring measure. A score of 1 or greater on PHQ-9 Item 9, or spontaneous report of current suicidal ideation at any point during the study, will trigger the suicidality and psychiatric safety procedures detailed under 'Monitoring and Quality Assurance'.
Parkinson disease or other non-AD neurodegenerative disorders (e.g., Huntington's disease)
Self-reported medical conditions
Diagnosis of cardiovascular disease or major cardiovascular procedures in the last 6 months (e.g., cardiac conduction abnormalities, heart attack, stroke, , angina pectoris, coronary-artery bypass grafting, percutaneous coronary intervention, cardioversion or ablation)
Diagnosis or treatment of cancer (except non-melanoma skin cancer) in the last 6 months
Concurrent use of anti-amyloid therapies (e.g., Donanemab, Lecanemab)
History of liver disease
Other exclusions
Lab values within the abnormal range (adjusted for age and sex where relevant) for renal function, reflex thyroid tests, and liver function
TICS-41 score ≤15
Score of >50% likelihood of significant hearing impairment according to the Hearing Handicap Inventory-Screening Version (HHIE-S)
Any other serious illness or condition that, in the opinion of the investigators, would preclude safe participation or completion of the study procedures
Concurrent participant in an ongoing clinical trial involving taking a study drug or supplement
Those who report "severe" for items 21-29 on the LiSERS questionnaire
UBACC (the University of California, San Diego Brief Assessment of Capacity to Consent) \< 11 indicating inability to provide . The clinical research coordinator will conduct a comprehension check of the consent form using the UBACC, which will require a perfect score of 11 out of 11 points to indicate capacity to provide informed consent. Prospective participants will be allowed two tries of the UBACC to achieve a score of 11.
Those with hearing impairment who do not report a clinician diagnosis of MCI or AD dementia given concerns for lack of awareness of objective memory decline which could lead to incorrect categorization without use of the TICS-41
Must reside in the states of Connecticut, Rhode Island, Massachusetts, Maine, New Hampshire, or Vermont and be able to have blood draws completed at a New England Quest location in those states.
Failure to complete the baseline blood collection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo pill taken daily for the 12 week study participation period. Placebo pills are in packaging identical to the LiO groups.
Dietary Supplement: Placebo
0.5 mg/day of LiO pills for the 12 week study participation period.
Dietary Supplement: Lithium Orotate (LiO)
1.0 mg/day of LiO pills for the 12 week study participation period.
Dietary Supplement: Lithium Orotate (LiO)
2.5 mg/day of LiO pills for the 12 week study participation period.
Dietary Supplement: Lithium Orotate (LiO)
5.0 mg/day of LiO pills for the 12 week study participation period.
Dietary Supplement: Lithium Orotate (LiO)
Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.
Placebo pill for the Lithium orotate.
Safety Monitoring
Blood samples will be collected at baseline and at a second timepoint prior to the end of the intervention (between 8 and 12 weeks during randomized treatment) for thyroid, liver, and kidney function monitoring. The safety measure is number (%) of participants with abnormal safety events. The safety measures monitored will be Thyroid Stimulating Hormone (TSH with reflex) above or below normal range, Liver Function Tests (LFTs) above normal range, and estimated glomerular filtration rate (EGFR) below 60. A safety event will be considered as an abnormality on any one of these indicators.
Time frame: 12 weeks
Tolerability: Study Withdrawal
Tolerability: Counts and percentages of participants who withdraw from study participation.
Time frame: 12 weeks
Tolerability: Adherence to Study Pills
Tolerability: Participants' adherence to assigned study pills will be monitored through regular web-based surveys and summarized descriptively; proportion of participants achieving predefined adherence thresholds (e.g. taking \>=75% of study supplements) will also be reported.
Time frame: 12 weeks
Recruitment
Recruitment number (count) and percent of planned enrollment.
Time frame: 6 months
Compliance: Questionnaire Data
Study compliance as completion rates (counts and percentages) of the web-based questionnaires.
Time frame: 12 weeks
Compliance: Blood Collection
Counts and percentages of individuals completing the first and final blood collections
Time frame: 12 weeks
Everyday Cognition(ECoG)
Survey measure of memory or thinking, using the ECOG, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in subjective cognition) that may be relevant to tolerability of lithium. ECOG items are scored 1-4 points, with worse cognition signified by higher scores. The total score range is 12-48 points.
Time frame: 12 weeks
Older Americans Resources and Services-Instrumental Activities of Daily Living (OARS-IADL)
Survey measure of functioning, using the OARS-IADL, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in everyday functioning related to cognition) that may be relevant to tolerability of lithium. A subset of questions from the IADL component of the OARS will be administered via survey. Each item is score 0, 1, or 2, or not applicable/not answered, where higher scores represent greater functional independence and lower scores represents lower functional independence. The total range is 0-12 points.
Time frame: 12 weeks
Functional Activities Questionnaire (FAQ)
Survey measure of functioning, using the FAQ, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in everyday functioning related to cognition) that may be relevant to tolerability of lithium. The FAQ features 10 items, each with values between 0 to 3 (or not applicable). The total score range is 0-30 points, with higher scores indicating higher functional dependency or impairment.
Time frame: 12 weeks
Patient Health Questionnaire-9 (PHQ-9)
Survey measure of functioning, using the PHQ-9, as this represents an important safety variable and/or common area of nuisance side effects (changes in mood and/or suicidality) that may be relevant to tolerability of lithium. The PHQ-9 features 9 items, each with values between 0 to 3 (or not applicable). The total score range is 0-27 points, with higher scores indicating higher levels of depressive symptoms.
Time frame: 12 weeks
Lithium Side Effects Rating Scale (LiSERS)
The LiSERS survey is used to measure absence, presence, and/or degree of severity (where applicable/present) to common or known potential side effects of lithium. The LiSERS features 30 items, for which respondents indicate yes or no; if yes, respondents further indicate degree of severity.
Time frame: 12 weeks
Additional Blood Biomarkers
Additional blood biomarkers (Lithium level, inflammatory markers, and ADRD biology markers, specifically pTau217) designed to further capture the effects of the supplement on the human body. These continuous measures of blood biomarkers will be reflected as levels or concentrations of the respective biomarkers.
Time frame: 12 weeks
Plan to share: No — Blinded study design; study group data will be analyzed in the aggregate. No Individual Participant Data will be shared.
Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.
Of 1,449 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 7 months is below that.
Counting every sponsor, half of 1,518 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →